Stockreport
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting [Yahoo! Finance]
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepoints for the entire 12-month study period Evolus dermal filler, Evolysse™ Smooth, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at 6 and 9 months The safety profiles were similar between the two Evolysse™ dermal filler products and Restylane-L and there were no treatment-related serious adverse events On track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days NEWPORT BEACH, Calif., May 20, 2024 BUSINESS WIRE Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline resul
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EOLS | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EOLS alerts
EOLS alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
NEWS
NEWS
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain [Yahoo! Finance][Yahoo! Finance]
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain[Business Wire]
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan [Yahoo! Finance][Yahoo! Finance]
- Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physicians [Yahoo! Finance][Yahoo! Finance]
- More
EOLS
SEC Filings
SEC Filings
- 6/11/24 - Form 8-K
- 6/6/24 - Form 4
- 6/6/24 - Form 144
- EOLS's page on the SEC website
- More